Contrasting Cambrex Corporation (CBM) & Marinus Pharmaceuticals (MRNS)
Cambrex Corporation (NYSE: CBM) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.
This is a summary of current ratings for Cambrex Corporation and Marinus Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cambrex Corporation currently has a consensus price target of $65.67, indicating a potential upside of 22.51%. Marinus Pharmaceuticals has a consensus price target of $7.00, indicating a potential upside of 70.73%. Given Marinus Pharmaceuticals’ higher probable upside, analysts plainly believe Marinus Pharmaceuticals is more favorable than Cambrex Corporation.
Risk & Volatility
Cambrex Corporation has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500.
Institutional and Insider Ownership
98.3% of Cambrex Corporation shares are owned by institutional investors. Comparatively, 28.8% of Marinus Pharmaceuticals shares are owned by institutional investors. 2.5% of Cambrex Corporation shares are owned by company insiders. Comparatively, 6.4% of Marinus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Cambrex Corporation and Marinus Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Cambrex Corporation and Marinus Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Cambrex Corporation||$515.45 million||3.40||$167.23 million||$2.76||19.42|
|Marinus Pharmaceuticals||N/A||N/A||-$22.16 million||($1.11)||-3.69|
Cambrex Corporation has higher revenue and earnings than Marinus Pharmaceuticals. Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cambrex Corporation, indicating that it is currently the more affordable of the two stocks.
Cambrex Corporation beats Marinus Pharmaceuticals on 9 of the 11 factors compared between the two stocks.
Cambrex Corporation Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.